ENDRA Life Sciences Inc. (NASDAQ: NDRA)
$5.1700
-0.1000 ( -1.52% ) 109.1K
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Market Data
Open
$5.1700
Previous close
$5.2700
Volume
109.1K
Market cap
$2.68M
Day range
$4.9300 - $5.7210
52 week range
$4.0100 - $4,882.5000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Jul 17, 2024 |
def | Proxies and info statements | 9 | Jun 25, 2024 |
ars | Annual reports | 76 | Jun 25, 2024 |
pre | Proxies and info statements | 9 | Jun 12, 2024 |
8-k | 8K-related | 16 | Jun 06, 2024 |
8-k | 8K-related | 16 | May 20, 2024 |
10-q | Quarterly Reports | 58 | May 14, 2024 |
8-k | 8K-related | 16 | May 14, 2024 |
8-k | 8K-related | 16 | May 10, 2024 |
8-k | 8K-related | 15 | May 03, 2024 |